Vaccine Technologies Companies

October 2022:

Merck & Co. and Moderna partnered to develop and commercialize a personalized cancer vaccine (PCV) mRNA-4157/V940. This collaboration leverages both companies' expertise in mRNA technology and personalized medicine.

August 2022:

Sanofi and Vaxart partnered to develop and commercialize a heat-stable oral rotavirus vaccine. This collaboration aims to improve vaccine access in low- and middle-income countries where refrigeration infrastructure is limited.

January 2023:

Valneva announced positive preliminary results from Phase 3 trial of its inactivated whole-virus COVID-19 vaccine candidate, VLA2001. The vaccine demonstrated good safety and immune response.

September 2022:

GSK reported successful topline results from Phase 3 trial of its RSV (respiratory syncytial virus) vaccine candidate for older adults. The vaccine showed significant reduction in severe RSV disease.

November 2022:

Pfizer-BioNTech received FDA approval for their updated bivalent COVID-19 booster vaccine targeting both the original strain and the Omicron BA.5 variant.

December 2022:

Seqirus launched its Fluad Quadrivalent recombinant influenza vaccine for adults in the US. This vaccine is the first recombinant influenza vaccine approved in the US and offers broader protection against four influenza strains.

• GlaxoSmithKline plc. (Brentford, U.K.)


• Sanofi (Paris, France)


• Pfizer Inc. (New York, U.S.)


• Merck & Co., Inc. (New Jersey, U.S.)


• Novartis AG (Basel, Switzerland)


• Emergent BioSolutions, Inc. (Maryland, U.S.)


• CSL Limited (Melbourne, Australia)


• Inovio Pharmaceuticals, Inc. (Pennsylvania, U.S.)


• Bavarian Nordic (Denmark)


• Mitsubishi Tanabe Pharma Corporation (Osaka, Japan)